Acurx Pharmaceuticals, Inc.(ACXP)Earnings, Financials & Key Ratios
ACXP•NASDAQ
$2.09
$5M mkt cap·Price updated May 6, 2026
AboutAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Show more
- Revenue$0
- EBITDA$0
- Net Income-$7.97B-56387.8%
- EPS (Diluted)-5.32+69.8%
- ROE-302.38%+43.4%
ACXP Key Insights
Acurx Pharmaceuticals, Inc. (ACXP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 76.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ACXP Price & Volume
Acurx Pharmaceuticals, Inc. (ACXP) stock price & volume — 10-year historical chart
Loading chart...
ACXP Growth Metrics
Acurx Pharmaceuticals, Inc. (ACXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56387.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM69.76%
Return on Capital
10 Years-341.68%
5 Years-267.25%
3 Years-388.68%
Last Year-
ACXP Peer Comparison
Acurx Pharmaceuticals, Inc. (ACXP) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACIU | 302.27M | 2.97 | -3.31 | -86.92% | -19.69% | -101.6% | 0.10 | |
 LPSN | 30.25M | 2.51 | -0.20 | -22% | -27.58% | |||
 NAOV | 512.71K | 1.90 | -0.14 | 12.05% | -133.04% | -8.41% | 0.19 | |
 PHAT | 1.01B | 12.67 | -4.18 | 216.93% | -61.95% | |||
 CLDX | 2.29B | 34.39 | -8.82 | -78.63% | -172.53% | -49.09% | 0.00 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 MTNB | 4.01M | 0.68 | -0.14 | -100% | -270.65% | 0.38 |
Compare ACXP vs Peers
Acurx Pharmaceuticals, Inc. (ACXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACXP Income Statement
Acurx Pharmaceuticals, Inc. (ACXP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 5.93M | 4.6M | 12.81M | 12.09M | 14.58M | 14.1M | 8.09B |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.42M | 2.4M | 10.78M | 7.34M | 8.53M | 8.7M | 6.26B |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 3.51M | 2.2M | 2.03M | 4.75M | 6.04M | 5.4M | 1.83B |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.81M▼ 178.6% | -12.09M▲ 5.6% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | 0▲ 100.0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 22.44% | -178.57% | 5.63% | -20.55% | 3.26% | 100% |
| EBITDA | 0 | 0 | -12.81M | -12.09M | -14.58M | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | - | 5.63% | -20.55% | 100% | - |
| D&A (Non-Cash Add-back) | 5.93M | 4.6M | 0 | 0 | 0 | 14.1M | 0 |
| EBIT | -5.93M | -4.6M | -12.81M | -12.09M | -14.58M | -14.1M | 0 |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 125.44M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 66.5K | 0 | 0 | 0 | 0 |
| Pretax Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.75M▼ 177.1% | -12.09M▲ 5.1% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | -7.97B▼ 56387.8% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.75M▼ 177.1% | -12.09M▲ 5.1% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | -7.97B▼ 56387.8% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | 22.44% | -177.12% | 5.14% | -20.55% | 3.26% | -56387.84% |
| Net Income (Continuing) | -5.93M | -4.6M | -12.75M | -12.09M | -14.58M | -14.1M | -7.97B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -12.00▲ 0% | -9.28▲ 22.7% | -24.96▼ 169.0% | -22.36▲ 10.4% | -23.01▼ 2.9% | -17.59▲ 23.6% | -5.32▲ 69.8% |
| EPS Growth % | - | 22.67% | -168.97% | 10.42% | -2.91% | 23.55% | 69.76% |
| EPS (Basic) | -12.00 | -9.28 | -24.96 | -22.36 | -23.01 | -17.59 | -5.32 |
| Diluted Shares Outstanding | 477.05K | 495.8K | 510.8K | 540.8K | 633.6K | 851.55K | 1.5M |
| Basic Shares Outstanding | 375.1K | 495.8K | 510.8K | 540.8K | 633.6K | 851.55K | 1.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
ACXP Balance Sheet
Acurx Pharmaceuticals, Inc. (ACXP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.53M | 3.22M | 13.25M | 9.38M | 7.71M | 3.86M | 7.56B |
| Cash & Short-Term Investments | 2.48M | 3.18M | 12.96M | 9.11M | 7.47M | 3.71M | 7.56B |
| Cash Only | 2.48M | 3.18M | 12.96M | 9.11M | 7.47M | 3.71M | 7.56B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 129.16K | 51.13K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 2.53M▲ 0% | 3.22M▲ 27.4% | 13.25M▲ 311.1% | 9.38M▼ 29.3% | 7.71M▼ 17.8% | 3.86M▼ 50.0% | 7.69B▲ 199215.9% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 27.36% | 311.11% | -29.25% | -17.78% | -49.96% | 199215.93% |
| Total Current Liabilities | 1.71M | 472.56K | 843.91K | 2.06M | 3.04M | 3.24M | 2.42B |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 16.63K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.31M | 317.07K | 508.34K | 542.89K | 716.31K | 537.63K | 2.42B |
| Current Ratio | 1.48x | 6.82x | 15.71x | 4.55x | 2.53x | 1.19x | 3.12x |
| Quick Ratio | 1.48x | 6.82x | 15.71x | 4.55x | 2.53x | 1.19x | 3.12x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 49.88K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 49.88K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.71M | 522.43K | 843.91K | 2.06M | 3.04M | 3.24M | 2.42B |
| Total Debt | 0 | 66.5K | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -2.48M | -3.11M | -12.96M | -9.11M | -7.47M | -3.71M | -7.56B |
| Debt / Equity | - | 0.02x | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 819.85K▲ 0% | 2.7M▲ 229.5% | 12.41M▲ 359.4% | 7.32M▼ 41.1% | 4.67M▼ 36.2% | 615.12K▼ 86.8% | 5.27B▲ 856413.1% |
| Equity Growth % | - | 229.52% | 359.37% | -41.06% | -36.2% | -86.82% | 856413.11% |
| Book Value per Share | 1.72 | 5.45 | 24.30 | 13.53 | 7.37 | 0.72 | 3514.74 |
| Total Shareholders' Equity | 819.85K | 2.7M | 12.41M | 7.32M | 4.67M | 615.12K | 5.27B |
| Common Stock | 10.02M | 16.5M | 10.22K | 11.63K | 14.47K | 17.03K | 2.35M |
| Retained Earnings | -9.2M | -13.8M | -26.55M | -38.64M | -53.22M | -67.32M | -75.29B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -9.2M | -13.8M | -26.55M | -38.64M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACXP Cash Flow Statement
Acurx Pharmaceuticals, Inc. (ACXP) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.99M | -3.35M | -5.01M | -7.54M | -9.8M | -10.38M | -6.79B |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 15.9% | -49.59% | -50.43% | -29.95% | -5.94% | -65271.28% |
| Net Income | -5.93M | -4.6M | -12.75M | -12.09M | -14.58M | -14.1M | -7.97B |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 900.43K | 1.27M | 6.74M | 3.3M | 3.77M | 3.44M | 1.25B |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 781.7K | 850.26K | 0 | 0 | 0 | -68.64M |
| Working Capital Changes | 1.05M | -801.17K | 141.28K | 1.25M | 1.01M | 284.09K | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | -129.16K | 78.03K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | -408.78M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.46M | 4.04M | 14.8M | 3.7M | 8.16M | 6.62M | 10.64B |
| Debt Issued (Net) | 0 | 66.5K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 3.81B |
| Other Financing | 0 | 0 | 0 | 13 | 2.22M | 210.2K | 10.64B |
| Net Change in Cash | 470.17K▲ 0% | 692.09K▲ 47.2% | 9.78M▲ 1313.6% | -3.85M▼ 139.3% | -1.64M▲ 57.4% | -3.77M▼ 130.1% | 3.85B▲ 102274.2% |
| Free Cash Flow | -3.99M▲ 0% | -3.35M▲ 15.9% | -5.01M▼ 49.6% | -7.54M▼ 50.4% | -9.8M▼ 29.9% | -10.38M▼ 5.9% | -6.79B▼ 65271.3% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | 15.9% | -49.59% | -50.43% | -29.95% | -5.94% | -65271.28% |
| FCF per Share | -8.35 | -6.76 | -9.82 | -13.95 | -15.47 | -12.19 | -4528.21 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.73x | 0.39x | 0.62x | 0.67x | 0.74x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACXP Key Ratios
Acurx Pharmaceuticals, Inc. (ACXP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -723.45% | -261.26% | -168.71% | -122.61% | -243.33% | -534.03% | -302.38% |
| Debt / Equity | - | 0.02x | - | - | - | - | - |
| FCF Conversion | 0.67x | 0.73x | 0.39x | 0.62x | 0.67x | 0.74x | 0.85x |
ACXP Frequently Asked Questions
Acurx Pharmaceuticals, Inc. (ACXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Acurx Pharmaceuticals, Inc. (ACXP) grew revenue by 0.0% over the past year. Growth has been modest.
Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $7.97B for fiscal year 2025.
Dividend & Returns
Acurx Pharmaceuticals, Inc. (ACXP) has a return on equity (ROE) of -302.4%. Negative ROE indicates the company is unprofitable.
Acurx Pharmaceuticals, Inc. (ACXP) generated $4.58B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ACXP
Acurx Pharmaceuticals, Inc. (ACXP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates